|
gptkbp:instance_of
|
gptkb:legal_case
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Lucentis
|
|
gptkbp:collaborated_with
|
academic institutions
|
|
gptkbp:collaborations
|
NHS and universities
|
|
gptkbp:completed
|
gptkb:2013
|
|
gptkbp:conducted
|
gptkb:United_Kingdom
several years
|
|
gptkbp:contributed_to
|
evidence-based medicine
understanding of AMD treatment
|
|
gptkbp:ends_at
|
aflibercept is effective
ranibizumab is effective
|
|
gptkbp:focuses_on
|
gptkb:psychologist
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
IVAN trial
|
|
gptkbp:includes
|
participants with wet AMD
|
|
gptkbp:influenced
|
gptkb:municipality
funding for future studies
|
|
gptkbp:is_aimed_at
|
determine effectiveness
|
|
gptkbp:is_analyzed_in
|
cost-effectiveness
long-term effects
visual function
retinal imaging data
|
|
gptkbp:is_cited_in
|
numerous publications
|
|
gptkbp:is_compared_to
|
gptkb:aflibercept
gptkb:ranibizumab
|
|
gptkbp:is_designed_to
|
improve patient outcomes
|
|
gptkbp:is_discussed_in
|
medical conferences
|
|
gptkbp:is_essential_for
|
clinical decision-making.
|
|
gptkbp:is_found_in
|
no significant difference in outcomes
|
|
gptkbp:is_informed_by
|
future research directions
|
|
gptkbp:is_involved_in
|
multidisciplinary teams
randomized controlled trial
multiple centers
over 600 participants
randomization process
|
|
gptkbp:is_monitored_by
|
independent committees
|
|
gptkbp:is_part_of
|
larger research initiatives
|
|
gptkbp:is_recognized_by
|
scientific rigor
|
|
gptkbp:launched
|
gptkb:2010
|
|
gptkbp:led_to
|
principal investigators
|
|
gptkbp:measures
|
visual acuity
|
|
gptkbp:notable_work
|
in peer-reviewed journals
|
|
gptkbp:performance
|
subsequent trials
|
|
gptkbp:provides
|
evidence for treatment protocols
|
|
gptkbp:provides_information_on
|
meta-analyses
|
|
gptkbp:published_by
|
gptkb:The_Lancet
|
|
gptkbp:received
|
ethical approval
|
|
gptkbp:receives_funding_from
|
government grants
|
|
gptkbp:registration
|
gptkb:Clinical_Trials.gov
|
|
gptkbp:reports_to
|
adverse events
safety outcomes
quality of life measures
|
|
gptkbp:research_interest
|
AMD treatments
|
|
gptkbp:result
|
gptkb:2015
|
|
gptkbp:significance
|
gptkb:legislation
ophthalmology community
|
|
gptkbp:sponsor
|
gptkb:National_Institute_for_Health_Research
|
|
gptkbp:uses
|
intravitreal injections
|
|
gptkbp:utilizes
|
patient-reported outcomes
blinding methods
|